Fusen Pharmaceutical Narrows Annual Loss Despite Revenue Decline

The latest announcement is out from Fusen Pharmaceutical Co., Ltd. ( (HK:1652) ).

Fusen Pharmaceutical reported revenue of RMB273.4 million for 2025, down 16.2% year on year, with gross profit falling 32.5% and gross margin narrowing from 49.9% to 40.2%. The board decided not to distribute a final dividend for 2025, in line with the prior year.

Despite weaker top-line performance, the company sharply reduced its net loss attributable to shareholders to RMB11.8 million from RMB188.8 million, helped by lower selling, administrative and research expenses and improved contributions from a joint venture. Net finance costs increased slightly, but operating losses narrowed significantly, signaling some stabilization after a challenging 2024.

The most recent analyst rating on (HK:1652) stock is a Hold with a HK$0.72 price target. To see the full list of analyst forecasts on Fusen Pharmaceutical Co., Ltd. stock, see the HK:1652 Stock Forecast page.

More about Fusen Pharmaceutical Co., Ltd.

Fusen Pharmaceutical Company Limited is a Cayman Islands-incorporated drug maker listed in Hong Kong. The group operates in the pharmaceutical industry, generating revenue from the sale of medicines and related healthcare products in mainland China, with a focus on prescription and over-the-counter formulations.

Average Trading Volume: 592,929

Technical Sentiment Signal: Buy

Current Market Cap: HK$911.7M

See more insights into 1652 stock on TipRanks’ Stock Analysis page.